Richtlinie: Labormedizinische diagnostik bei der therapie mit TPMT (thiopurin-s-methyltransferase)-abhängigen pharmaka

Thomas Deufel; Reinhard Geßner; Karl J. Lackner; Matthias Schwab; Werner Steimer; Michael Steiner; Nicolas Von Ahsen; Michael Kiehntopf

doi:10.1515/LabMed.2004.063

Richtlinie: Labormedizinische diagnostik bei der therapie mit TPMT (thiopurin-s-methyltransferase)-abhängigen pharmaka

Translated title of the contribution: Guidelines for the laboratory management of thiopurine drug therapy

Thomas Deufel, Reinhard Geßner, Karl J. Lackner, Matthias Schwab, Werner Steimer, Michael Steiner, Nicolas Von Ahsen, Michael Kiehntopf

Default

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Thiopurines (azathioprine, 6-mercaptopurine, 6-thioguanine) are widely used as immunosuppressive agents in a variety of diseases. Patients completely deficient in thiopurine S-methyltransferase (TPMT) activity regularly exhibit serious toxicity, mainly hematological cytopenias. For this reason, complete TPMT-deficiency must be excluded prior to thiopurine treatment. This can be achieved either by measuring TPMT-activity in erythrocytes (TPMT-phenotyping) or by genotyping TPMT alleles. Observing the applicable limitations, both methods can be used alternatively. Complex diagnostic findings obtained with one method, however, have to be verified by the alternative method, respectively (genotyping/phenotyping).

Translated title of the contribution	Guidelines for the laboratory management of thiopurine drug therapy
Original language	German
Pages (from-to)	477-482
Number of pages	6
Journal	LaboratoriumsMedizin
Volume	28
Issue number	6
DOIs	https://doi.org/10.1515/LabMed.2004.063
State	Published - 2004

Access to Document

10.1515/LabMed.2004.063

Cite this

@article{4f634231b91d4cadbf915b9bf0e248a6,

title = "Richtlinie: Labormedizinische diagnostik bei der therapie mit TPMT (thiopurin-s-methyltransferase)-abh{\"a}ngigen pharmaka",

abstract = "Thiopurines (azathioprine, 6-mercaptopurine, 6-thioguanine) are widely used as immunosuppressive agents in a variety of diseases. Patients completely deficient in thiopurine S-methyltransferase (TPMT) activity regularly exhibit serious toxicity, mainly hematological cytopenias. For this reason, complete TPMT-deficiency must be excluded prior to thiopurine treatment. This can be achieved either by measuring TPMT-activity in erythrocytes (TPMT-phenotyping) or by genotyping TPMT alleles. Observing the applicable limitations, both methods can be used alternatively. Complex diagnostic findings obtained with one method, however, have to be verified by the alternative method, respectively (genotyping/phenotyping).",

keywords = "6-mercaptopurine (6-MP), Adverse effects, Azathioprine, Drug monitoring, Genotype-phenotype correlation, Immunosuppressive agents, Pharmacogenetics, TPMT-deficiency, TPMT-polymorphisms, Thioguanine, Thiopurine methyltransferase (TPMT), Thiopurines",

author = "Thomas Deufel and Reinhard Ge{\ss}ner and Lackner, {Karl J.} and Matthias Schwab and Werner Steimer and Michael Steiner and {Von Ahsen}, Nicolas and Michael Kiehntopf",

year = "2004",

doi = "10.1515/LabMed.2004.063",

language = "Deutsch",

volume = "28",

pages = "477--482",

journal = "LaboratoriumsMedizin",

issn = "0342-3026",

publisher = "De Gruyter Open Ltd.",

number = "6",

}

TY - JOUR

T1 - Richtlinie

T2 - Labormedizinische diagnostik bei der therapie mit TPMT (thiopurin-s-methyltransferase)-abhängigen pharmaka

AU - Deufel, Thomas

AU - Geßner, Reinhard

AU - Lackner, Karl J.

AU - Schwab, Matthias

AU - Steimer, Werner

AU - Steiner, Michael

AU - Von Ahsen, Nicolas

AU - Kiehntopf, Michael

PY - 2004

Y1 - 2004

N2 - Thiopurines (azathioprine, 6-mercaptopurine, 6-thioguanine) are widely used as immunosuppressive agents in a variety of diseases. Patients completely deficient in thiopurine S-methyltransferase (TPMT) activity regularly exhibit serious toxicity, mainly hematological cytopenias. For this reason, complete TPMT-deficiency must be excluded prior to thiopurine treatment. This can be achieved either by measuring TPMT-activity in erythrocytes (TPMT-phenotyping) or by genotyping TPMT alleles. Observing the applicable limitations, both methods can be used alternatively. Complex diagnostic findings obtained with one method, however, have to be verified by the alternative method, respectively (genotyping/phenotyping).

AB - Thiopurines (azathioprine, 6-mercaptopurine, 6-thioguanine) are widely used as immunosuppressive agents in a variety of diseases. Patients completely deficient in thiopurine S-methyltransferase (TPMT) activity regularly exhibit serious toxicity, mainly hematological cytopenias. For this reason, complete TPMT-deficiency must be excluded prior to thiopurine treatment. This can be achieved either by measuring TPMT-activity in erythrocytes (TPMT-phenotyping) or by genotyping TPMT alleles. Observing the applicable limitations, both methods can be used alternatively. Complex diagnostic findings obtained with one method, however, have to be verified by the alternative method, respectively (genotyping/phenotyping).

KW - 6-mercaptopurine (6-MP)

KW - Adverse effects

KW - Azathioprine

KW - Drug monitoring

KW - Genotype-phenotype correlation

KW - Immunosuppressive agents

KW - Pharmacogenetics

KW - TPMT-deficiency

KW - TPMT-polymorphisms

KW - Thioguanine

KW - Thiopurine methyltransferase (TPMT)

KW - Thiopurines

UR - http://www.scopus.com/inward/record.url?scp=11144319855&partnerID=8YFLogxK

U2 - 10.1515/LabMed.2004.063

DO - 10.1515/LabMed.2004.063

M3 - Artikel

AN - SCOPUS:11144319855

SN - 0342-3026

VL - 28

SP - 477

EP - 482

JO - LaboratoriumsMedizin

JF - LaboratoriumsMedizin

IS - 6

ER -

Richtlinie: Labormedizinische diagnostik bei der therapie mit TPMT (thiopurin-s-methyltransferase)-abhängigen pharmaka

Abstract

Access to Document

Other files and links

Fingerprint

Cite this